Effectiveness and Safety of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis
← catalyst calendarSponsored by Almirall, S.A. (industry) · ALM.MC — their whole pipeline →.
Phase
Phase 3
Status
Completed
Study type
Interventional
Design
Na · None · Treatment
Enrollment
260actual
Sites
33
Countries
Germany, Netherlands, United Kingdom
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-11-20 | actual | When the study began enrolling |
| Primary completion | 2025-06-25 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-06-25 | actual | The whole study's end, after follow-up |
| First posted | 2023-08-14 | actual | When this record first appeared on the registry |
| Results posted | 2026-07-17 | actual | When the sponsor posted results to the registry |
| Record updated | 2026-07-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Atopic Dermatitis
- Eczema
Intervention
- Biological: Lebrikizumab
Primary outcome
what the primary-completion date above is the date OFPercentage of Participants Who Achieved Eczema Area and Severity Index (EASI) Total Score Less Than or Equal to (<=) 7 at Week 24
measured At Week 24
Posted documents
hosted by the registry — we link, never re-serveStudy Protocolposted 2024-07-29 · 8.2 MB · Prot_000.pdf
Statistical Analysis Planposted 2025-07-18 · 7.2 MB · SAP_001.pdf
Permalink · ALM.MC's whole pipeline · Catalyst calendar · Every registered study · What changed